These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 11412650)

  • 1. [Systematic review of clinical trials on the treatment of rheumatoid arthritis with tumour necrosis factor alpha inhibitors].
    Reneses S; Pestana L
    Med Clin (Barc); 2001 May; 116(16):620-8. PubMed ID: 11412650
    [No Abstract]   [Full Text] [Related]  

  • 2. Strengths and limitations of a systematic review on DMARDs for rheumatoid arthritis.
    Smolen JS; Aletaha D
    Nat Clin Pract Rheumatol; 2008 Jun; 4(6):296-7. PubMed ID: 18461061
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical trial outcome of anti-tumour necrosis factor alpha therapy in rheumatic arthritis.
    Choy E
    Cytokine; 2004 Nov 21-Dec 7; 28(4-5):158-61. PubMed ID: 15588689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour necrosis factor-alpha blockers in rheumatoid arthritis: review of the clinical experience.
    Richard-Miceli C; Dougados M
    BioDrugs; 2001; 15(4):251-9. PubMed ID: 11437690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of tumor necrosis factor for rheumatoid arthritis.
    Moreland LW
    J Rheumatol Suppl; 1999 May; 57():7-15. PubMed ID: 10328137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [TNF-alpha antagonists in therapy of rheumatoid arthritis].
    Gross WL; Gause A
    Z Rheumatol; 2003 Jun; 62(3):217. PubMed ID: 12931691
    [No Abstract]   [Full Text] [Related]  

  • 7. Biologic therapy for early rheumatoid arthritis: the latest evidence.
    Castro-Rueda H; Kavanaugh A
    Curr Opin Rheumatol; 2008 May; 20(3):314-9. PubMed ID: 18388524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumor necrosis factor-alpha agents for rheumatoid arthritis: assessing longterm safety.
    Hyrich KL; Silman AJ
    J Rheumatol; 2006 May; 33(5):831-3. PubMed ID: 16652412
    [No Abstract]   [Full Text] [Related]  

  • 9. New tumour necrosis factor inhibitors for rheumatoid arthritis: are there benefits from extending choice?
    Scott DL; Cope A
    Ann Rheum Dis; 2009 Jun; 68(6):767-9. PubMed ID: 19435722
    [No Abstract]   [Full Text] [Related]  

  • 10. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis.
    Roubille C; Richer V; Starnino T; McCourt C; McFarlane A; Fleming P; Siu S; Kraft J; Lynde C; Pope J; Gulliver W; Keeling S; Dutz J; Bessette L; Bissonnette R; Haraoui B
    Ann Rheum Dis; 2015 Mar; 74(3):480-9. PubMed ID: 25561362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do all drugs and treatments for rheumatoid arthritis have the same efficacy?
    Weisman MH
    Nat Clin Pract Rheumatol; 2008 Jun; 4(6):298-9. PubMed ID: 18431369
    [No Abstract]   [Full Text] [Related]  

  • 12. When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step?
    Smolen JS; Weinblatt ME
    Ann Rheum Dis; 2008 Nov; 67(11):1497-8. PubMed ID: 18854512
    [No Abstract]   [Full Text] [Related]  

  • 13. Assessing the safety of new arthritis drugs: are we there yet?
    Suissa S
    J Rheumatol; 2008 Dec; 35(12):2295-7. PubMed ID: 19040315
    [No Abstract]   [Full Text] [Related]  

  • 14. Definition of discontinuation of anti-tumour necrosis factor therapy in rheumatoid arthritis: a preliminary proposal.
    Braun J; Sieper J; van der Heijde D
    Ann Rheum Dis; 2003 Oct; 62(10):1023-4. PubMed ID: 12972492
    [No Abstract]   [Full Text] [Related]  

  • 15. Perforating folliculitis associated with tumour necrosis factor-alpha inhibitors administered for rheumatoid arthritis.
    Gilaberte Y; Coscojuela C; Vázquez C; Roselló R; Vera J
    Br J Dermatol; 2007 Feb; 156(2):368-71. PubMed ID: 17223880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abatacept.
    Vital EM; Emery P
    Drugs Today (Barc); 2006 Feb; 42(2):87-93. PubMed ID: 16541185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis.
    Rémy A; Avouac J; Gossec L; Combe B
    Clin Exp Rheumatol; 2011; 29(1):96-103. PubMed ID: 21269578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of perioperative tumour necrosis factor α inhibitors in rheumatoid arthritis patients undergoing arthroplasty: a systematic review and meta-analysis.
    Goodman SM; Menon I; Christos PJ; Smethurst R; Bykerk VP
    Rheumatology (Oxford); 2016 Mar; 55(3):573-82. PubMed ID: 26447162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The future role of anti-tumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis.
    Camussi G; Lupia E
    Drugs; 1998 May; 55(5):613-20. PubMed ID: 9585859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis.
    Moss ML; Sklair-Tavron L; Nudelman R
    Nat Clin Pract Rheumatol; 2008 Jun; 4(6):300-9. PubMed ID: 18414459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.